Clinical trials: SGLT2 Inhibitor
Prediabetes
Evaluation of Empagliflozin vs Standard Care in Veterans With Prediabetes
Prediabetes effects 96 million people 18 years of age or older. It is important to identify treatment options to slow or prevent progression to diabetes.
- Trial name
- PREVNT (NCT06828731)
- Testing
- Empagliflozin 10mg daily, Lifestyle education
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Charles George VA Medical Center
Diabetic Nephropathies
Effect of Sodium Glucose co Transporter 2 Inhibitor ( SGLT2) on Proteinuria in Diabetic Patients
Diabetes Mellitus is the leading cause of end stage renal disease. As proven by many studies , controlling proteinuria can delay the progression to end stage renal disease.This work will study the effect of sodium glucose co…
- Trial name
- NCT03573102
- Testing
- SGLT2 inhibitor, ACE inhibitor
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Nahla H Tohami
Type 2 Diabetes
The Effect of a SGLT2 Inhibitor on Glucose Flux, Lipolysis and Exercise in Type 2 Diabetes
The study is a randomised double blind placebo control cross over trial with 4 weeks washout period. The expected duration of participant participation is 103 days.
- Trial name
- SINGLED (NCT04219124)
- Testing
- IMP oral tablet
- Where
- United Kingdom
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University of Leicester
Diabetes Mellitus, Type 2
Meta-analysis in Post-marketing Surveillances for SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to integrate the post-marketing surveillances data (Specified use-results surveys on long-term treatment) of the 6 SGLT2 inhibitors approved or applied in Japan and to evaluate the safety and efficacy…
- Trial name
- NCT02284269
- Testing
- SGLT2 Inhibitors
- Volunteers
- 18,000 people
- Sponsor
- Pharmaceuticals and Medical Devices Agency, Japan